Epidemiology And Pediatric Significance
- Chronicity Risk: While $<5\%$ of adults infected with Hepatitis B develop chronic infection, $>90\%$ of perinatally infected infants and $30–50\%$ of children infected between ages 1 to 5 years progress to life-long Chronic Hepatitis B (CHB).
- Disease Burden in India: Intermediate endemicity ($2–4\%$ HBsAg prevalence; approx. 40 million carriers). The National Viral Hepatitis Control Program (NVHCP) aims to eliminate viral hepatitis as a public health threat by 2030.
- Clinical Course in Children: Classically begins with a prolonged immune-tolerant phase (HBeAg positive, very high HBV DNA $>10^7\text{ IU/mL}$, normal ALT, minimal fibrosis), transitioning over decades to the immune-active phase (ALT elevation, fluctuating viral loads, histological inflammation), carrying long-term risk of cirrhosis and hepatocellular carcinoma (HCC).
WHO 2024 Simplified Treatment Criteria For Adolescents & Children
The WHO 2024 Hepatitis B Guidelines substantially expanded and simplified treatment indications to overcome previous under-diagnosis and treatment delays:
flowchart TD
A["Child / Adolescent Confirmed HBsAg Positive (> 6 months)"] --> B["<b>Comprehensive Staging:</b><br>• ALT, HBeAg / Anti-HBe, HBV DNA PCR<br>• Non-Invasive Fibrosis Assessment: APRI Score / FibroScan (VCTE)<br>• Screen for Family History of Cirrhosis / HCC"]
B --> C{"Check Treatment Indications (WHO 2024)"}
C -->|"Indication Met"| D["<b>INITIATE FIRST-LINE ANTIVIRAL THERAPY:</b><br>1. Significant Fibrosis: APRI > 0.5 or FibroScan > 7.0–8.0 kPa (regardless of ALT)<br>2. HBV DNA > 2,000 IU/mL + Persistently Elevated ALT (> ULN on 2 tests over 6–12 mo)<br>3. Cirrhosis (Clinical / Radiological / FibroScan) regardless of HBV DNA or ALT<br>4. Family history of HCC / Cirrhosis + High HBV DNA (> 2,000 IU/mL)<br>5. Extrahepatic Manifestations (e.g., Membranous Nephropathy, Polyarteritis Nodosa)"]
C -->|"No Indication (Immune-Tolerant Phase)"| E["<b>Monitoring Without Therapy:</b><br>• Clinical review + ALT every 6 months<br>• HBV DNA every 12 months<br>• Annual non-invasive fibrosis check"]
Note on Pediatric ALT Thresholds: Standard adult laboratory reference limits overestimate normal pediatric ALT. True upper limits of normal (ULN) in pediatrics are approximately $26\text{ U/L}$ for boys and $22\text{ U/L}$ for girls.
High-Barrier Antiviral Arsenal
Low-barrier agents (Lamivudine, Adefovir) are obsolete due to high rates of emergent resistance ($>70\%$ at 5 years).
| Antiviral Agent | Approved Pediatric Age & Weight | Daily Dosage | Key Clinical Features |
|---|---|---|---|
| Entecavir (ETV) | $\ge 2\text{ years}$ ($\ge 10\text{ kg}$) | $0.015\text{ mg/kg/day}$ (max $0.5\text{ mg}$ once daily). Available as oral solution ($0.05\text{ mg/mL}$) and scored tablets. | Potent cyclopentyl guanosine analogue; high genetic barrier to resistance in treatment-naive children ($<1\%$ resistance at 5 years). |
| Tenofovir Disoproxil Fumarate (TDF) | $\ge 2\text{ years}$ ($\ge 10\text{ kg}$) | $8\text{ mg/kg/day}$ (max $300\text{ mg}$ once daily). Available as tablets ($150, 200, 250, 300\text{ mg}$). | Zero documented clinical resistance; excellent antiviral potency. Requires monitoring for renal proximal tubulopathy (Fanconi syndrome) and decreased bone mineral density (BMD). |
| Tenofovir Alafenamide (TAF) | $\ge 6\text{ years}$ ($\ge 25\text{ kg}$) | Fixed dose: $25\text{ mg}$ once daily with food. | Targeted pro-drug; achieves high intracellular diphosphate concentrations in hepatocytes at $1/10\text{th}$ the systemic plasma exposure of TDF. Markedly superior renal and bone safety profile. |
Prevention Of Mother-To-Child Transmission (PMTCT)
Perinatal transmission carries the highest lifetime chronicity risk ($>90\%$). The standard PMTCT bundle includes:
- Maternal Antiviral Prophylaxis:
- Universal HBsAg screening in early pregnancy.
- Initiate oral TDF $300\text{ mg}$ daily from 28 weeks gestation if maternal $\text{HBV DNA} > 200,000\text{ IU/mL}$ ($>5.3\log_{10}\text{ IU/mL}$) or if HBeAg is positive when quantitative DNA is unavailable.
- Continue until delivery or up to 2–12 weeks postpartum. Safe in breastfeeding.
- Infant Immunoprophylaxis (Within 12 Hours of Birth):
- Hepatitis B Vaccine: Monovalent birth dose ($0.5\text{ mL}$ IM) administered in the anterolateral thigh.
- Hepatitis B Immune Globulin (HBIG): $0.5\text{ mL}$ ($100–200\text{ IU}$) IM administered at a contralateral anatomical site.
- Subsequent routine doses at 6, 10, and 14 weeks via pentavalent / hexavalent vaccines.
- Post-Vaccination Serological Testing (PVST):
- Performed at 9 to 12 months of age (after completion of the primary series and clearance of maternal anti-HBs).
- Test for both HBsAg (to assess infection status) and anti-HBs titers ($>10\text{ mIU/mL}$ confirms protective seroconversion).
Non-Invasive Staging (APRI Score & Transient Elastography)
- Invasive liver biopsy is rarely necessary today.
- APRI (AST to Platelet Ratio Index):
$$\text{APRI} = \frac{(\text{AST Level} / \text{AST Upper Limit of Normal})}{\text{Platelet Count } (10^9/\text{L})} \times 100$$
- $\text{APRI} > 0.5$ suggests significant fibrosis in children; $>1.5$ indicates advanced fibrosis/cirrhosis.
- Vibration-Controlled Transient Elastography (FibroScan):
- Liver stiffness measurement (LSM) $>7.0–8.0\text{ kPa}$ indicates significant fibrosis ($F \ge 2$).
- LSM $>11–12\text{ kPa}$ indicates cirrhosis ($F4$), triggering immediate antiviral initiation.